To study the clinical characteristics of patients of non-small cell lung cancer (NSCLC) who had E19-Del and L852R gene mutation.

This study summarized total 498 patients of NSCLC who received gene tests in respiratory and critical care medicine department in Tangdu hospital, The Fourth Military Medical University from Jul. 2012 to Jul. 2018. The correlations between the E19-Del and L852R gene mutation and the clinical characteristics of the patients were retrospective analyzed.

E19-Del gene mutation rate was declining in the following groups: the age less than 50 years, the age more than 70 years and the age between 50 years and 70 years (χ²=5.984, P=0.050). Non-smokers had higher E19-Del gene mutation rate than patients who smoke more than 20 cigarettes a day (χ²=4.328, P=0.037). E19-Del gene mutation rate also declined in the following groups: adenocarcinoma and other types of NSCLC (χ²=12.197, P=0.000). And E19-Del gene mutation rate was declining as the reducing of pathological stage (χ²=6.625, P=0.036). L858R gene mutation rate of female was higher than male (χ²=13.755, P=0.000). As the lessening of patients smoking degree, L858R gene mutation rate was declining (χ²=7.234, P=0.027). L858R gene mutation rate also declined in the following groups: adenocarcinoma and other types of NSCLC (χ²=5.538, P=0.021). L858R gene mutation of patients who had pleura metastasis was higher than who did not (χ²=4.004, P=0.045).

There is some significant difference of clinical features in E19-Del gene mutation with non-smoking and young people in NSCLC. Then L858R gene mutation rate was high in non-smoking women and patients who had pleura metastasis. Both E19-Del and L858R gene mutation rate had no significant correlations with whether patients had different tumor position, diabetes, high blood pressure, bone metastasis, cranium metastasis and lymphomatous metastasis.